Infixion is awarded third NIH SBIR phase 1 grant to develop therapeutics for NF1
Infixion announced its third NIH SBIR Phase 1 grant from the National Institute of Neurological Disorders and Stroke (NINDS). Infixion has received two previous NIH SBIR Phase 1 grants for NF1 drug discovery (2020 and 2021), and this third NIH grant will enable Infixion to further advance efforts to correct for the lack of normal […]